PubMed Health⌕ Search

Biomedical subjects

D Hunninghake

Publications and source records attributed to D Hunninghake.

28 records · Page 2Linked to original sources
PubMed1992

Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia.

Recommended doses of bile-acid binding resins have an established hypocholesterolemic effect, but data on responses to low doses, especially in women and subjects with moderate hypercholesterolemia, are sparse. A double-blind, placebo-controlled, randomized trial of 3 low doses of colestipol hydrochloride was conducted in women and men with moderate hypercholesterolemia. Men and women with plasma low-density lipoprotein (LDL) cholesterol concentrations greater than 4 mmol/liter (155 mg/dl) and triglyceride concentrations less than 2.82 mmol/liter (250 mg/dl) were recruited for the study. Eligible patients (54 women and 98 men) were placed on the American Heart Association step I diet 6 weeks before randomization. Participants were subsequently assigned to 1 of 4 drug treatment groups (placebo, and 5, 10 and 15 g/day of colestipol in 2 divided doses) for an additional 12 weeks. Of the 152 patients randomized, 141 completed all aspects of the study. For the treatment groups--placebo, and 5, 10 and 15 g of colestipol--LDL cholesterol reductions (mmol/liter) were observed respectively (n = 141): 0.10 +/- 0.49 (2.7%), 0.65 +/- 0.41 (16.3%), 0.98 +/- 0.36 (22.8%) and 1.17 +/- 0.47 (27.2%) (p less than 0.001). Similar changes were observed in total cholesterol and apolipoprotein B concentrations. The apolipoprotein B/LDL cholesterol ratio increased significantly with increasing colestipol dosage. Modest but insignificant changes in plasma triglyceride levels occurred, and high-density lipoprotein cholesterol levels remained unchanged. A dose of 5 g/day of colestipol achieved 51% of the LDL cholesterol reduction noted with 15 g/day. Low-dose colestipol therapy is effective in the treatment of patients with moderate hypercholesterolemia.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1983

Habitual physical activity and high-density lipoprotein cholesterol in men with primary hypercholesterolemia. The Lipid Research Clinics Coronary Primary Prevention Trial.

The association of habitual physical activity with plasma high-density lipoprotein (HDL) cholesterol and total triglyceride (TG) was examined in 7106 asymptomatic 35-59-year-old white men with primary type II hyperlipoproteinemia who attended the second screening visit of the Lipid Research Clinics Coronary Primary Prevention Trial. Subjects were rated by usual level of physical activity at work and outside of work and the frequency of strenuous physical labor or exercise. By each of these three criteria, physical activity was monotonically related to HDL cholesterol and TG: the most physically active men had the highest HDL cholesterol and lowest TG levels. With respect to physical activity outside of work, for example, mean HDL cholesterol and TG were 46.4 and 152.1 mg/dl, respectively, in the most active group, and 41.4 and 186.7 mg/dl in the most sedentary group. Physical activity remained significantly predictive of HDL cholesterol and TG when other known correlates of these plasma constituents--age, Quetelet index, plasma total cholesterol, cigarette smoking, alcohol intake, and clinic--were controlled individually by two-way analyses of variance or jointly by analysis of covariance. The association of physical activity with very low density lipoprotein cholesterol was parallel to but weaker than its association with TG. Low-density lipoprotein and total cholesterol were not significantly related to physical activity.

Adult↗
PubMed1982

Alteration in blood pressures associated with combined alcohol and oral contraceptive use-the lipid research clinics prevalence study.

Alterations in systolic and diastolic blood pressure levels associated with combined oral contraceptive (OC) and alcohol use were investigated in white women 20-49 years of age from 10 North American Lipid Research Clinics study populations. OC users had systolic pressures 2-3 mm Hg higher than non-users, but no difference was noted for diastolic pressures. Among non-OC users, both systolic and diastolic blood pressures were positively associated with reported alcohol consumption, though participants reporting no alcohol use had blood pressures slightly higher than those reporting minimal intake. The blood pressure correlates of OC's and alcohol appeared to be independent, and systolic pressures levels were over 8 mm Hg higher in those reporting heavier alcohol intake and OC use than among those reporting minimal alcohol intake and no OC use.

Adult↗
PubMed1982

Alterations in clinical chemistry measures associated with oral contraceptive and estrogen use: the Lipid Research Clinics Program Prevalence Study.

The associations of current oral contraceptive (OC) or estrogen use and mean levels of a variety of clinical chemistry measurements have not been previously described in large, free-living populations. We compared mean fasting measurements of eight clinical chemistry tests (alkaline phosphatase, serum glutamic oxaloacetic transaminase [SGOT], total bilirubin, globulin, thyroxine, creatinine, uric acid and plasma glucose) adjusted for age, body mass, education, alcohol use, smoking and study population variation in approximately 1,500 white women from nine North American Lipid Research Clinic populations. Compared to hormone nonusers of the same age, OC users aged 20 to 39 years had significantly lower mean values of serum alkaline phosphatase, SGOT, total bilirubin and plasma glucose, while serum globulin, thyroxine and creatinine levels were significantly higher. Mean uric acid values were not significantly different. Estrogen users aged 50 to 69 years had significantly lower mean values of alkaline phosphatase and total bilirubin and significantly higher thyroxine and uric acid levels as compared to hormone nonusers aged 50 to 69 years.

Adult↗
PubMed1981

Alterations of plasma lipid and lipoprotein levels associated with benzodiazepine use--the LRC Program Prevalence Study.

In a study of white adults from 10 North American Lipid Research Clinics populations, plasma lipid and lipoprotein levels in benzodiazepine (diazepam, chlordiazepoxide, flurazepam) users were compared to both the entire population of non-users and matched control non-users. Significantly higher plasma triglyceride and very low density lipoprotein cholesterol levels and by one method of analysis, lower high density lipoprotein cholesterol levels were noted in male benzodiazepine users. No significant differences were noted in total plasma cholesterol or low density lipoprotein cholesterol levels.

Adult↗
PubMedDate not supplied

LDL-cholesterol as a determinant of coronary heart disease.

The Adult Treatment Panel of the National Cholesterol Education Program identified high levels of LDL-cholesterol as a major risk factor in developing CHD and as the primary target for cholesterol-lowering therapy. Low levels of HDL were recognized as a contributing risk factor for CHD, and the panel recommended that low HDL-cholesterol levels be raised by changes in diet and lifestyle. When drug therapy is required for high LDL-cholesterol levels in the presence of low HDL levels, it would appear reasonable to choose one that both markedly reduces LDL-cholesterol and raises HDL-cholesterol.

Animals↗